Daily spirometry in an acute exacerbation of adult cystic fibrosis patients

Michael J. Stephen, Alex Long, Chad Bonsall, Jeffrey B. Hoag, Smita Shah, Dorothy Bisberg, Douglas Holsclaw, Laurie Varlotta, Stanley Fiel, Doantrang Du, Robert Zanni, Denis Hadjiliadis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1. Of the 15 subjects with a sustainable 10% increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10% improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.

Original languageEnglish (US)
Pages (from-to)258-264
Number of pages7
JournalChronic Respiratory Disease
Volume15
Issue number3
DOIs
StatePublished - Aug 1 2018

Fingerprint

Spirometry
Cystic Fibrosis
Anti-Bacterial Agents

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Stephen, M. J., Long, A., Bonsall, C., Hoag, J. B., Shah, S., Bisberg, D., ... Hadjiliadis, D. (2018). Daily spirometry in an acute exacerbation of adult cystic fibrosis patients. Chronic Respiratory Disease, 15(3), 258-264. https://doi.org/10.1177/1479972317743756
Stephen, Michael J. ; Long, Alex ; Bonsall, Chad ; Hoag, Jeffrey B. ; Shah, Smita ; Bisberg, Dorothy ; Holsclaw, Douglas ; Varlotta, Laurie ; Fiel, Stanley ; Du, Doantrang ; Zanni, Robert ; Hadjiliadis, Denis. / Daily spirometry in an acute exacerbation of adult cystic fibrosis patients. In: Chronic Respiratory Disease. 2018 ; Vol. 15, No. 3. pp. 258-264.
@article{2cc484c3c81d4b98bedfabb37b34637f,
title = "Daily spirometry in an acute exacerbation of adult cystic fibrosis patients",
abstract = "To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10{\%} increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10{\%} increase in FEV1. Of the 15 subjects with a sustainable 10{\%} increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10{\%} improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.",
author = "Stephen, {Michael J.} and Alex Long and Chad Bonsall and Hoag, {Jeffrey B.} and Smita Shah and Dorothy Bisberg and Douglas Holsclaw and Laurie Varlotta and Stanley Fiel and Doantrang Du and Robert Zanni and Denis Hadjiliadis",
year = "2018",
month = "8",
day = "1",
doi = "10.1177/1479972317743756",
language = "English (US)",
volume = "15",
pages = "258--264",
journal = "Chronic Respiratory Disease",
issn = "1479-9723",
publisher = "SAGE Publications Ltd",
number = "3",

}

Stephen, MJ, Long, A, Bonsall, C, Hoag, JB, Shah, S, Bisberg, D, Holsclaw, D, Varlotta, L, Fiel, S, Du, D, Zanni, R & Hadjiliadis, D 2018, 'Daily spirometry in an acute exacerbation of adult cystic fibrosis patients', Chronic Respiratory Disease, vol. 15, no. 3, pp. 258-264. https://doi.org/10.1177/1479972317743756

Daily spirometry in an acute exacerbation of adult cystic fibrosis patients. / Stephen, Michael J.; Long, Alex; Bonsall, Chad; Hoag, Jeffrey B.; Shah, Smita; Bisberg, Dorothy; Holsclaw, Douglas; Varlotta, Laurie; Fiel, Stanley; Du, Doantrang; Zanni, Robert; Hadjiliadis, Denis.

In: Chronic Respiratory Disease, Vol. 15, No. 3, 01.08.2018, p. 258-264.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Daily spirometry in an acute exacerbation of adult cystic fibrosis patients

AU - Stephen, Michael J.

AU - Long, Alex

AU - Bonsall, Chad

AU - Hoag, Jeffrey B.

AU - Shah, Smita

AU - Bisberg, Dorothy

AU - Holsclaw, Douglas

AU - Varlotta, Laurie

AU - Fiel, Stanley

AU - Du, Doantrang

AU - Zanni, Robert

AU - Hadjiliadis, Denis

PY - 2018/8/1

Y1 - 2018/8/1

N2 - To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1. Of the 15 subjects with a sustainable 10% increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10% improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.

AB - To help answer the question of length of intravenous antibiotics during an acute exacerbation of cystic fibrosis (CF), we had subjects to follow daily home spirometry while on intravenous antibiotics. CF patients, 18 and older, with an acute exacerbation requiring intravenous antibiotics had a daily FEV1. The average time to a 10% increase over their initial sick FEV1 was calculated, as well as the time to a new baseline. A total of 25 subjects completed the study. Ten of the 25 subjects did not have a sustainable 10% increase in FEV1. Of the 15 subjects with a sustainable 10% increase in FEV1, it took 5.2 days (±4.5) after day 1, while a new baseline was achieved on average at 6.6 days (±4.8) after day 1. Given the wide range of time to a 10% improvement and new baseline, it is recommended there should be flexibility in length of intravenous antibiotics in CF, not by a preset number.

UR - http://www.scopus.com/inward/record.url?scp=85051277859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051277859&partnerID=8YFLogxK

U2 - 10.1177/1479972317743756

DO - 10.1177/1479972317743756

M3 - Article

VL - 15

SP - 258

EP - 264

JO - Chronic Respiratory Disease

JF - Chronic Respiratory Disease

SN - 1479-9723

IS - 3

ER -

Stephen MJ, Long A, Bonsall C, Hoag JB, Shah S, Bisberg D et al. Daily spirometry in an acute exacerbation of adult cystic fibrosis patients. Chronic Respiratory Disease. 2018 Aug 1;15(3):258-264. https://doi.org/10.1177/1479972317743756